luspatercept (Reblozyl) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA First in Class Fast Track FDA
AACT ChEMBL DrugBank
Back

Drug Pricing Summary

VA Big4

$2563.4400 - $7689.9800

VA FSS

$3423.8900 - $10271.6500

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
luspatercept 25 mg (INJECTION) $2563.4400 VA Big4
  • Reblozyl (1)
    		•  Celgene Corporation
    luspatercept 25 mg (INJECTION) $3423.8900 VA FSS
  • Reblozyl (1)
    		•  Celgene Corporation
    luspatercept 75 mg (INJECTION) $7689.9800 VA Big4
  • Reblozyl (1)
    		•  Celgene Corporation
    luspatercept 75 mg (INJECTION) $10271.6500 VA FSS
  • Reblozyl (1)
    		•  Celgene Corporation

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue